Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 09 2022 - 8:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that
it will host a conference call and live audio webcast on Wednesday,
August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022
financial results and provide an update on its business and
pipeline.
To access the call, please dial 1-877-704-4453
(domestic) or 1-201-389-0920 (international) and refer to
conference ID 13731565. The audio webcast can be accessed under
“Events and Presentations” in the Investor and Media section of the
Company’s website
at www.sperotherapeutics.com. The archived
webcast will also be available on Spero’s website for 30 days
following the call.
About Spero TherapeuticsSpero
Therapeutics is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing, and
commercializing novel treatments for bacterial infections,
including multi-drug resistant bacterial infections and rare
diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain microorganisms, in adult patients
who have limited treatment options; tebipenem HBr is not
FDA-approved.
For more information,
visit https://sperotherapeutics.com.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceTJenkins@sperotherapeutics.com (617) 798-4039
Media Inquiries:
media@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024